NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) – Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical company announced today that ‘she signed a memorandum of understanding with tella, Inc. (“tella”) to collaborate in the field of immunotherapy for the treatment of cancer.
tella is a Japanese company that contributes to the advancement of cancer therapy through cancer vaccine research and development. Tella dendritic cell vaccine therapy aims to increase the dendritic cell population and strengthen the attack system against cancers. In 2019, Tella dendritic cell vaccine therapy was provided to approximately 12,200 patients at 28 medical facilities across Japan.
Beroni and tella recognize that the resources possessed by each party and their respective affiliates, such as technology, knowledge and networks, are of great value to the other. In this context, they intend to build strategic partnerships in the field of immunotherapy for the treatment of cancer, such as the conduct of clinical trials on dendritic cell vaccine and gamma delta T cells in Japan and in China, the crossing of the shareholders of the two parties, the technical exchange between the two parties. and other strategic developments.
“Dendritic cell vaccine therapy has been studied worldwide as an ‘advanced anti-cancer immune cell therapy’ that ensures more reliable action against cancer cells using the patient’s own immune cells, than other vaccines. anticancer. It should also be effective for prevention or recurrence after standard treatment, ”said Tomoyuki Taira, president of tella, Inc.“ We look forward to a long-term and cooperative working relationship with Beroni. This collaboration can help us deliver dendritic cell vaccine therapy to more people in more geographies and more cancer patients can be cured.
“This is an important step in advancing our clinical trials in the treatment of cancer. Thanks to this partnership, we can conduct clinical trials with tella in Japan. Thanks to our multi-center clinical studies, we can include a larger number of participants in various geographies and compare results between centers, thus increasing the generalizability of our study results, ”commented Jacky Zhang, President and CEO of Beroni Group. “We are delighted to be working with tella to develop new cell therapies using their advanced dendritic cell vaccine therapy. We are also looking forward to developing our new gamma delta T cell based cellular immunotherapy with tella in Japan. “
About Beroni Group Limit
Beroni Group is an Australia-based biopharmaceutical company dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diverse portfolio includes FDA / CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceuticals, and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, the United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
About Tella, Inc
tella, Inc is a Japanese company listed on the Tokyo Stock Exchange (TSE: 2191) that provides technical and operational know-how associated with cellular drugs, including dendritic cell vaccine therapy, to affiliated medical institutions. He also conducts clinical research on new regenerative medicine and cell medicine such as immunotherapy, cell treatment devices and pharmaceuticals involving the use of dendritic cell vaccine therapy.
Looking to the future Statements Warning
This press release contains forward-looking statements or information, within the meaning of US and Australian securities laws applicable to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by forward-looking statements. Therefore, readers should not place undue reliance on forward-looking statements. In general, forward-looking statements can be identified by the use of terms such as “anticipate”, “anticipate”, “expect”, “may”, “continue”, “could”, “estimate”, “anticipate”. , “Plan”, “intend”, “believe”, “potential” and similar expressions.
The forward-looking information contained in this press release is based on the opinions, estimates and assumptions of the management of the company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as ‘other factors that management currently considers appropriate and reasonable. under the circumstances. Forward-looking statements involve important risks, uncertainties and assumptions, and there can be no assurance that such statements, or their underlying risks, uncertainties and assumptions, will prove to be correct. Factors that could cause actual results or events to differ materially include, without limitation, risks relating to laws, rules and regulations applicable to the Company as well as to the industry in which it operates (including including with respect to taxes and other levies), economic or market conditions at national and global level, currency fluctuations, the risks inherent in other entities at a similar stage of development and the sector in which the Company currently, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and / or its products or services, regulatory actions or litigation (including product liability claims) and failure to conclude agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is only provided on the date it is provided and, except as required by applicable law, the Company disclaims any intention or obligation to update such forward-looking information, whether as a result of new information, in the future. events or otherwise.
For more information, please contact our IR Consultants at:
Dragon Gate Investment Partners LLC
Phone: +1 (646) -801-2803
Email: [email protected]